

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIPPO LIMITED

力寶有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 226)

LIPPO CHINA RESOURCES LIMITED

力寶華潤有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 156)

JOINT ANNOUNCEMENT

INSIDE INFORMATION

UPDATE ON THE CONDITIONAL EXIT OFFER FOR THE PROPOSED VOLUNTARY DELISTING OF HEALTHWAY MEDICAL CORPORATION LIMITED

Reference is made to the joint announcements issued by Lippo and LCR dated 3 July 2023 and 29 September 2023 (the “**Announcements**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as defined in the Announcements.

This joint announcement is made pursuant to rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules).

The respective Boards of Lippo and LCR wish to update their respective shareholders and potential investors on the further developments in relation to the Delisting and Exit Offer.

On 16 October 2023, Healthway announced that it had obtained a letter from the SGX-ST indicating that the SGX-ST has no objection to the Delisting subject to the following: (a) Healthway making an immediate announcement of the proposed Delisting; and (b) submission of a written confirmation from Healthway that it is not aware of any information that will have a material bearing on investors’ decision which has yet to be announced by Healthway. Healthway has announced that the aforementioned conditions have been met.

Following the receipt of the SGX-ST’s no-objection letter, Healthway will be delisted from the official list of the SGX-ST after the close of the Exit Offer. The Exit Offer will remain open until 5:30 p.m. (Singapore time) on 26 October 2023.

For more details on the latest update on the Delisting and the Exit Offer, please refer to the announcement made by Healthway posted on the website of each of the SGX-ST (at www.sgx.com) and Healthway dated 16 October 2023.

Shareholders and potential investors of each of Lippo and LCR are advised to exercise caution when dealing in the shares of each of Lippo and LCR.

By Order of the Board
LIPPO LIMITED
John Luen Wai Lee
*Managing Director and
Chief Executive Officer*

By Order of the Board
LIPPO CHINA RESOURCES LIMITED
John Luen Wai Lee
Chief Executive Officer

Hong Kong, 16 October 2023

As at the date of this announcement, the board composition of each of Lippo and LCR is as follows:

Lippo

Executive Directors:

Dr. Stephen Riady (*Chairman*)
Mr. John Luen Wai Lee
(*Managing Director and
Chief Executive Officer*)
Mr. Brian Riady

Non-executive Directors:

Mr. Jark Pui Lee
Mr. Leon Nim Leung Chan

Independent Non-executive Directors:

Mr. King Fai Tsui
Mr. Victor Ha Kuk Yung
Ms. Min Yen Goh

LCR

Executive Directors:

Dr. Stephen Riady (*Chairman*)
Mr. John Luen Wai Lee
(*Chief Executive Officer*)
Mr. James Siu Lung Lee
Mr. Brian Riady

Non-executive Director:

Mr. Leon Nim Leung Chan

Independent Non-executive Directors:

Mr. Edwin Neo
Mr. Victor Ha Kuk Yung
Ms. Min Yen Goh